Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

IgA nephropathy: an update.

Bruce A Julian1, Jan Novak

  • 1Department of aMedicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA. bjulian@uab.edu

Current Opinion in Nephrology and Hypertension
|June 19, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to Loss of GalNAc-T14 links O-glycosylation defects to alterations in B cell homing in IgA nephropathy.

The Journal of clinical investigation·2026
Same author

Inhibition of p65 NF-κB enhances production of galactose-deficient IgA1 through suppression of <i>C1GALT1</i> and SP1 in plasmablast-like cell subpopulations.

bioRxiv : the preprint server for biology·2026
Same author

Proteomic Analysis of Circulating IgA1-Containing Immune Complexes in Patients with IgA Nephropathy.

Kidney international reports·2025
Same author

Kidney injury and colocalization of complement C3, IgA, and IgG in glomerular immune-complex deposits of patients with IgA nephropathy or IgA vasculitis with nephritis.

Kidney international·2025
Same author

IgA Nephropathy in the Elderly.

Kidney international reports·2025
Same author

Loss of GalNAc-T14 links O-glycosylation defects to alterations in B cell homing in IgA nephropathy.

The Journal of clinical investigation·2025
Same journal

Sex differences in renal acid-base regulation.

Current opinion in nephrology and hypertension·2026
Same journal

Primary prevention of chronic kidney disease in type 2 diabetes mellitus with sodium-glucose cotransporter 2 inhibitors.

Current opinion in nephrology and hypertension·2026
Same journal

Financial and policy challenges of delivering kidney replacement therapies in resource-limited settings.

Current opinion in nephrology and hypertension·2026
Same journal

The role of kir4.1/Kir5.1 in mediating the effect of angiotensin-II on Na-Cl-cotransporter.

Current opinion in nephrology and hypertension·2026
Same journal

Role of the calcium-sensing receptor in regulating calcium transport in the thick ascending limb.

Current opinion in nephrology and hypertension·2026
Same journal

Social determinants of chronic kidney disease: from association to clinical and population action.

Current opinion in nephrology and hypertension·2026
See all related articles

Patients with IgA nephropathy produce galactose-deficient IgA1, which drives disease progression. Current treatments focus on managing symptoms, as IgA nephropathy-specific therapies are still lacking.

Area of Science:

  • Nephrology
  • Immunology
  • Pathogenesis of Glomerulonephritis

Background:

  • Immunoglobulin A nephropathy (IgAN) is characterized by IgA1 with aberrant O-linked glycans in the hinge region.
  • Galactose-deficient IgA1 (Gd-IgA1) plays a crucial role in IgAN pathogenesis.

Purpose of the Study:

  • To review recent advances in understanding Gd-IgA1's role in IgAN pathogenesis.
  • To discuss current therapeutic strategies for IgAN in the absence of disease-specific treatments.

Main Methods:

  • Review of recent scientific literature on IgA nephropathy.
  • Analysis of the pathogenetic mechanisms involving Gd-IgA1 and mesangial cells.

Main Results:

  • Gd-IgA1 forms immune complexes that activate mesangial cells, leading to cytokine release and extracellular matrix production.

Related Experiment Videos

  • While understanding of Gd-IgA1 glycosylation and mesangial cell interactions has advanced, IgAN-specific therapies remain unavailable.
  • Current cornerstone therapies involve suppressing the renin-angiotensin-aldosterone system (RAAS) using ACE inhibitors and/or ARBs.
  • Glucocorticoids and cyclophosphamide may benefit select IgAN patients.

    • Conclusions:

    • Further research into Gd-IgA1 synthesis, immune complex formation, and mesangial cell interactions is crucial.
    • Identifying novel therapeutic targets is essential for preventing and managing glomerular and interstitial damage in IgAN.
    • A deeper understanding of IgAN pathogenesis may lead to the development of IgAN-specific treatments.